Evidence map›Paper›PMID 42382290›Full record

ArticleInternational journal of pharmaceutics: X2026

Integrating in vitro aerosol characterization and cross-species PBPK modeling to predict human lung exposure of inhaled therapeutic proteins.

Jin-Long Liu, Ya-Xin Liu, Xue-Juan Zhang, Guang-Lin Wang, Jie Huang, Han-Feng Zhang, Nuo Xu, Sheng-Nan Zhang, Xiao Yue, Xu-Xia Liang and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of pharmaceutics: X, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Jin-Long LiuCenter of Clinical Pharmacology, The Third Xiangya Hospital, Central South University, Changsha, Hunan 410013, China.
Ya-Xin LiuCenter of Clinical Pharmacology, The Third Xiangya Hospital, Central South University, Changsha, Hunan 410013, China.
Xue-Juan ZhangCollege of Pharmacy, Jinan University, Guangzhou, Guangdong 510632, China.
Guang-Lin WangSchool of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou, Guangdong 510006, China.
Jie HuangCenter of Clinical Pharmacology, The Third Xiangya Hospital, Central South University, Changsha, Hunan 410013, China.
Han-Feng ZhangXiangya School of Pharmaceutical Sciences, Central South University, Changsha, Hunan 410013, China.
Nuo XuXiangya School of Pharmaceutical Sciences, Central South University, Changsha, Hunan 410013, China.
Sheng-Nan ZhangDepartment of Pharmacy, The Third Xiangya Hospital, Central South University, Changsha, Hunan 410013, China.
Xiao YueCollege of Pharmacy, Jinan University, Guangzhou, Guangdong 510632, China.
Xu-Xia LiangCollege of Pharmacy, Jinan University, Guangzhou, Guangdong 510632, China.
Yin-Jia LuoCollege of Pharmacy, Jinan University, Guangzhou, Guangdong 510632, China.
Heng-Xin PengKexing Biopharm Co., Ltd, Shenzhen, Guangdong 518057, China.
Qi PeiDepartment of Pharmacy, The Third Xiangya Hospital, Central South University, Changsha, Hunan 410013, China.
Yun KuangCenter of Clinical Pharmacology, The Third Xiangya Hospital, Central South University, Changsha, Hunan 410013, China.
Guo-Ping YangCenter of Clinical Pharmacology, The Third Xiangya Hospital, Central South University, Changsha, Hunan 410013, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inhalation therapy provides a rapid onset and avoids first-pass metabolism, making it a key non-invasive delivery strategy for therapeutic proteins. However, predicting pulmonary exposure is challenging due to aerosol properties and lung anatomy. This study is the first to construct an integrated in vitro aerosol characterization and cross-species extrapolation pulmonary physiologically-based pharmacokinetic (PBPK) model for inhaled therapeutic proteins. Using recombinant human interferon-α1b (rhIFN-α1b) as a model drug, aerosol aerodynamic properties and delivery performance were evaluated at different concentrations (15-60 μg/mL) and inhalation devices (mouthpiece vs. facemask). The multiple path particle dosimetry (MPPD) model was used to predict particle deposition in the lungs. Further, a pulmonary PBPK model for rhIFN-α1b in mice and healthy adults was developed and validated through pharmacokinetic studies. Results showed that delivery efficiency decreased with concentration, and the mouthpiece outperformed the mask. MPPD simulations indicated that the mouthpiece reduced oropharyngeal retention and enhanced alveolar deposition. Larger particle sizes led to reduced alveolar deposition. The PBPK model accurately predicted rhIFN-α1b exposure in the lungs and serum of healthy adults, with 85% of C

Indexed as

Cross-species extrapolationIn vitro aerosol characterizationPhysiologically-based pharmacokineticsPulmonary deliveryTherapeutic proteins

Identifiers

PMID42382290
PMCPMC13315771

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.